稳经济、进万企|光银国际助力绿竹生物-B于香港主板成功上市

2023-5-8光银国际

2023年5月8日，光银国际作为联席牵头经办人及资本市场中介人，成功助力北京绿竹生物技术股份有限公司（股票代号：2480.HK，以下简称“绿竹生物-B”）于香港主板挂牌上市。

此次IPO募集资金将用于核心产品LZ901（用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起带状疱疹的疫苗）的临床开发、制造及商业化、K3（用于治疗各种自身免疫性疾病的生物仿制药）的临床开发及制造、建设公司于珠海的商业生产设施和营运资金及其他一般公司用途。

绿竹生物-B是一家致力于开发创新型人类疫苗和治疗性生物制剂，以预防和控制传染性疾病，并治疗癌症和自身免疫性疾病的生物技术公司。自2001年成立以来，公司专注于人类医学领域，并凭借对免疫学和蛋白质工程的理解，建立了技术平台，令公司可开发效率优良、高纯度及稳定性有所改善的重组疫苗及抗体在研产品。截至最后实际可行日期，公司的产品管线包括三款临床阶段的在研产品，包括公司的核心产品LZ901，以及四款临床前阶段的在研产品。截至同日，公司有与核心产品相关的两项研发专利及七项待批准申请。

光银国际作为此次IPO项目的联席牵头经办人及资本市场中介人，为公司成功挂牌上市保驾护航，做出了重要的贡献。光银国际严格按照时间表与保荐人共同推进项目进程，以专业一流的综合投行服务获得了公司的高度认可及赞赏。

As a Joint Lead Manager and Capital Market Intermediary, CEBI assisted Beijing Luzhu Biotechnology Co., Ltd. (Stock Code: 2480.HK, “Luzhu Biotechnology”) to get listed on the Main Board of the Stock Exchange of Hong Kong on 8th May 2023.

The net proceeds from the Global Offering will be used for clinical development, manufacturing and commercialization of the Company’s Core Product, LZ901, clinical development and manufacturing of K3, construction of the Company’s second-phase commercial manufacturing facility in Zhuhai and working capital and other general corporate purposes.

Luzhu Biotechnology is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since its inception in 2001, the Company has focused on human medicine and has established technology platforms with its understanding of immunology and protein engineering, which empowers the Company to develop the recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability. As of the Latest Practicable Date, the Company’s product pipeline consisted of three clinical-stage product candidates, including its Core Product LZ901, and four pre-clinical-stage product candidates. As of the same date, Luzhu Biotechnology had two invention patents and seven pending applications relating to its Core Product.

As a Joint Lead Manager and Capital Market Intermediary, CEBI has made crucial contributions to the successful listing of the Company. CEBI strictly followed the timetable to push forward the IPO project with the sponsor and other intermediaries. The professionalism and service quality of CEBI have been highly recognized by the Company.

免责声明
请注意光银国际投资有限公司及其下属公司（统称“光银国际”）可能在过去12个月内与上述某些公司有投资银行业务关系或其他业务关系（如配售代理、牵头经办人、保荐人、包销商或自营买卖证券），同时亦可能持有上述公司的财务权益及/或证券或衍生工具。本文章内容及插图仅作资料及一般参考之用，并不构成投资要约或要约邀请，也不是投资、法律、会计、税务或其他意见，任何人士不应根据本文章内容及插图做出任何投资决定，光银国际将不承担任何责任。同时光银国际并不保证本文章已提供所有市场流通信息。本文章属撰文者的意见，不一定与光银国际其他业务领域或部门的意见一致，如有任何修改，恕不另行通知。同时，未经光银国际事先允许，任何人不得全部或部分修改、翻版、分发、转载、复制、发表或引用本文章，光银国际对任何第三方的该等行为保留追述权利。完整免责声明，请见光银国际官方网站：WWW.CEBI.COM.HK